We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

45 hedge funds and large institutions have $81.8M invested in Ovid Therapeutics in 2017 Q2 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

32.49% more ownership

Funds ownership: 0% → 32.49% (+32%)

Holders
45
Holders Change
+45
Holders Change %
–
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
45
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$23.7M
2
BlackRock
BlackRock
New York
+$14.6M
3
Jennison Associates
Jennison Associates
New York
+$8.49M
4
TCM
Tekla Capital Management
Massachusetts
+$7M
5
RG
Redmile Group
California
+$5.86M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$18.3M +$23.7M +1,814,847 New
BlackRock
2
BlackRock
New York
$11.8M +$14.6M +1,121,085 New
Jennison Associates
3
Jennison Associates
New York
$6.74M +$8.49M +650,074 New
TCM
4
Tekla Capital Management
Massachusetts
$5.23M +$7M +535,824 New
O
5
OppenheimerFunds
New York
$4.46M +$5.55M +425,000 New
RG
6
Redmile Group
California
$4.24M +$5.86M +448,781 New
Ameriprise
7
Ameriprise
Minnesota
$3.76M +$4.68M +358,468 New
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$3.64M +$4.72M +361,640 New
BBA
9
Baker Bros. Advisors
New York
$3.5M +$4.35M +333,333 New
SFM
10
Sphera Funds Management
Israel
$3.04M +$3.99M +305,674 New
CAM
11
Cormorant Asset Management
Massachusetts
$2.35M +$2.92M +223,972 New
CC
12
Casdin Capital
New York
$2.33M +$2.89M +221,700 New
DCM
13
Driehaus Capital Management
Illinois
$2.29M +$2.84M +217,841 New
Deutsche Bank
14
Deutsche Bank
Germany
$2.16M +$2.69M +205,826 New
Victory Capital Management
15
Victory Capital Management
Texas
$1.37M +$1.71M +131,000 New
Vanguard Group
16
Vanguard Group
Pennsylvania
$1.04M +$1.3M +99,317 New
Goldman Sachs
17
Goldman Sachs
New York
$923K +$1.15M +87,943 New
Northern Trust
18
Northern Trust
Illinois
$604K +$751K +57,547 New
State Street
19
State Street
Massachusetts
$520K +$648K +49,600 New
SSA
20
Schonfeld Strategic Advisors
New York
$367K +$457K +35,000 New
LOAMU
21
Lombard Odier Asset Management (USA)
New York
$328K +$408K +31,250 New
NC
22
Nexthera Capital
New York
$320K +$399K +30,543 New
Citigroup
23
Citigroup
New York
$301K +$374K +28,629 New
Geode Capital Management
24
Geode Capital Management
Massachusetts
$292K +$364K +27,842 New
AA
25
ALPS Advisors
Colorado
$233K +$290K +22,206 New
1
2

OVID Hedge Fund Activity: Q2 2017 in Review

45 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2017, worth a combined $81.8M.

Buyers outnumbered sellers: 45 funds opened new OVID positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $23.7M.

  • 45 institutional investors held Ovid Therapeutics (OVID) as of Q2 2017, up from 0 in Q1 2017.
  • Funds reported $81.8M of Ovid Therapeutics stock for Q2 2017.
  • 45 funds opened new Ovid Therapeutics positions in Q2 2017 and 0 closed out, a net change of +45 holders.
  • The largest Ovid Therapeutics buyer in Q2 2017 was Fidelity Investments, an estimated $23.7M added.

Based on aggregated 13F filings for Q2 2017.